Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ajinomoto Pharmaceuticals and Albireo have signed a licensing agreement to develop and commercialize elobixibat in Indonesia, Japan, South Korea, Thailand, Taiwan and Vietnam.
Subscribe to our email newsletter
Under the agreement, Ajinomoto gains exclusive rights to elobixibat and in return the company will pay pay a significant upfront fee, milestones and tiered double-digit royalties to Albireo.
Elobixibat is an investigational drug in development for chronic constipation and irritable bowel syndrome with constipation.
Ajinomoto president and CEO Tomoyasu Toyoda said the company will work together with Albireo to file the NDA and launch the product as quickly as possible.
"Elobixibat will be the starting point of the growing collaborative relationship between Albireo and Ajinomoto Pharmaceuticals in the gastrointestinal area," Toyoda added.